A Phase 3 Randomized Double-blind Study Comparing TR-701 FA and Linezolid in Ventilated Gram-positive Nosocomial Pneumonia

Trial Profile

A Phase 3 Randomized Double-blind Study Comparing TR-701 FA and Linezolid in Ventilated Gram-positive Nosocomial Pneumonia

Recruiting
Phase of Trial: Phase III

Latest Information Update: 13 Nov 2017

At a glance

  • Drugs Tedizolid (Primary) ; Linezolid
  • Indications Nosocomial pneumonia
  • Focus Registrational; Therapeutic Use
  • Sponsors Cubist Pharmaceuticals; Merck Sharp & Dohme; Trius Therapeutics
  • Most Recent Events

    • 10 May 2017 This trial has been completed in Austria.
    • 29 Nov 2016 Planned End Date changed from 1 Jan 2018 to 1 Oct 2018.
    • 29 Nov 2016 Planned primary completion date changed from 1 Jan 2018 to 1 Oct 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top